{"title":"直肠给药系统(RDDS)在炎症性肠病(IBD)治疗中的应用:现状、挑战和新兴策略","authors":"Prakash Monika , Maitreyi Darbha , S. Reneeka , Kirti Gupta , H.R. Tejashree , Mohamed Shabi , Shwetha Krishnamurthy","doi":"10.1016/j.jddst.2025.107567","DOIUrl":null,"url":null,"abstract":"<div><div>Rectal drug delivery systems (RDDS) are increasingly being explored as a practical and targeted approach for managing inflammatory bowel disease (IBD), particularly in cases of ulcerative colitis (UC) and Crohn's disease (CD). Unlike oral or injectable therapies that often struggle with systemic side effects and poor targeting, RDDS allow medications to act directly at the site of inflammation, improving drug bioavailability and reducing unwanted systemic exposure. Over time, researchers have sought to address the limitations of rectal administration, including discomfort, variable retention, and formulation instability. These challenges are being mitigated through innovative design strategies. Recent advances in drug carriers, such as nanoparticles, mucoadhesive hydrogels, thermosensitive formulations, and microbiome-responsive systems, have facilitated more precise and sustained drug release. In parallel, natural compounds, particularly phytochemicals, are being incorporated into these carriers to impart anti-inflammatory and antioxidant properties while minimizing side effects. However, despite promising laboratory outcomes, clinical translation remains limited. Challenges such as anatomical variability, patient compliance, and long-term formulation stability continue to slow progress. This review explores recent developments in RDDS for IBD, reflecting on both the scientific advances made and the gaps that remain. It also highlights the growing need for patient-centric, interdisciplinary strategies, encompassing advances in nanoparticle-based carriers, polymeric and microbiome-responsive systems along with phytocompound-based formulations to fully realise the therapeutic potential of rectal delivery in IBD care<strong>.</strong></div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"114 ","pages":"Article 107567"},"PeriodicalIF":4.9000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rectal drug delivery systems (RDDS) in inflammatory bowel disease (IBD) therapy: current status, challenges and emerging strategies\",\"authors\":\"Prakash Monika , Maitreyi Darbha , S. Reneeka , Kirti Gupta , H.R. Tejashree , Mohamed Shabi , Shwetha Krishnamurthy\",\"doi\":\"10.1016/j.jddst.2025.107567\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Rectal drug delivery systems (RDDS) are increasingly being explored as a practical and targeted approach for managing inflammatory bowel disease (IBD), particularly in cases of ulcerative colitis (UC) and Crohn's disease (CD). Unlike oral or injectable therapies that often struggle with systemic side effects and poor targeting, RDDS allow medications to act directly at the site of inflammation, improving drug bioavailability and reducing unwanted systemic exposure. Over time, researchers have sought to address the limitations of rectal administration, including discomfort, variable retention, and formulation instability. These challenges are being mitigated through innovative design strategies. Recent advances in drug carriers, such as nanoparticles, mucoadhesive hydrogels, thermosensitive formulations, and microbiome-responsive systems, have facilitated more precise and sustained drug release. In parallel, natural compounds, particularly phytochemicals, are being incorporated into these carriers to impart anti-inflammatory and antioxidant properties while minimizing side effects. However, despite promising laboratory outcomes, clinical translation remains limited. Challenges such as anatomical variability, patient compliance, and long-term formulation stability continue to slow progress. This review explores recent developments in RDDS for IBD, reflecting on both the scientific advances made and the gaps that remain. It also highlights the growing need for patient-centric, interdisciplinary strategies, encompassing advances in nanoparticle-based carriers, polymeric and microbiome-responsive systems along with phytocompound-based formulations to fully realise the therapeutic potential of rectal delivery in IBD care<strong>.</strong></div></div>\",\"PeriodicalId\":15600,\"journal\":{\"name\":\"Journal of Drug Delivery Science and Technology\",\"volume\":\"114 \",\"pages\":\"Article 107567\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drug Delivery Science and Technology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1773224725009700\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Delivery Science and Technology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1773224725009700","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Rectal drug delivery systems (RDDS) in inflammatory bowel disease (IBD) therapy: current status, challenges and emerging strategies
Rectal drug delivery systems (RDDS) are increasingly being explored as a practical and targeted approach for managing inflammatory bowel disease (IBD), particularly in cases of ulcerative colitis (UC) and Crohn's disease (CD). Unlike oral or injectable therapies that often struggle with systemic side effects and poor targeting, RDDS allow medications to act directly at the site of inflammation, improving drug bioavailability and reducing unwanted systemic exposure. Over time, researchers have sought to address the limitations of rectal administration, including discomfort, variable retention, and formulation instability. These challenges are being mitigated through innovative design strategies. Recent advances in drug carriers, such as nanoparticles, mucoadhesive hydrogels, thermosensitive formulations, and microbiome-responsive systems, have facilitated more precise and sustained drug release. In parallel, natural compounds, particularly phytochemicals, are being incorporated into these carriers to impart anti-inflammatory and antioxidant properties while minimizing side effects. However, despite promising laboratory outcomes, clinical translation remains limited. Challenges such as anatomical variability, patient compliance, and long-term formulation stability continue to slow progress. This review explores recent developments in RDDS for IBD, reflecting on both the scientific advances made and the gaps that remain. It also highlights the growing need for patient-centric, interdisciplinary strategies, encompassing advances in nanoparticle-based carriers, polymeric and microbiome-responsive systems along with phytocompound-based formulations to fully realise the therapeutic potential of rectal delivery in IBD care.
期刊介绍:
The Journal of Drug Delivery Science and Technology is an international journal devoted to drug delivery and pharmaceutical technology. The journal covers all innovative aspects of all pharmaceutical dosage forms and the most advanced research on controlled release, bioavailability and drug absorption, nanomedicines, gene delivery, tissue engineering, etc. Hot topics, related to manufacturing processes and quality control, are also welcomed.